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1752demonstrated excellent outcomes
with the HeartMate (HM) II
(Thoratec, Pleasanton, Califor-
nia) when used by clinicians in the
commercial (i.e., outside of the
clinical trial) setting (2). Of note,
success for the BTT indication is
generally deﬁned as “alive on de-
vice or transplanted by 180 days,”
and is by deﬁnition accomplished
in patients who are candidates
for cardiac transplantation (i.e.,
relatively young and without ma-
jor comorbidities).
See page 1758
More recently, following a
pivotal multicenter trial conducted from 2005 to 2010 (3),
which had a primary endpoint of survival at 2 years on the
original device and without disabling stroke, the HM II was
also approved for destination therapy (DT). DT candidates
are not eligible for cardiac transplantation, are typically older,
and frequently have a higher burden of comorbidities.
Management of this patient cohort is more complex, and
results obtained in a strictly regulated clinical trial setting
may not be achievable in clinical commercial use. Accord-
ingly, and to fulﬁll requirements by the FDA for a post-
approval (PA) study, we compared outcomes of the ﬁrst
HeartMate II DT patients in commercial use to DT patients
in the pivotal trial (TR). We hypothesized that LVAD pa-
tients who underwent implantation for DT in commercial
use would have comparable outcomes to the clinical trial.
Methods
Study design and patient population. The study was a
prospective evaluation of the ﬁrst 247 consecutive HM II
patients who underwent implantation after FDA approval of
the device and who were preoperatively identiﬁed for DT in
INTERMACS (Interagency Registry for Mechanically
Assisted Circulatory Support). Patients in the PA study
group were enrolled at 61 centers from January to September
2010 and followed for 2 years after implantation. These
patients were compared with a historical control group
comprised of the primary data cohort of 133 patients
implanted with the HM II in the multicenter clinical pivotal
trial (TR) from March 2005 to May 2007 at 34 centers,
which led to FDA approval of the device for DT (3).
Patients with advanced heart failure who were ineligible
for heart transplantation and who were refractory to opti-
mal medical management were considered for enrollment.
Details of the inclusion and exclusion criteria for the DT
clinical trial have been published elsewhere (see the Online
Appendix in Slaughter et al. [3]). All patients had a minimalclinical follow-up since implantation for at least 2 years or
until they met the primary endpoint of the study.
Data collection. For the TR group, data were retrieved
from the original clinical trial database. For the PA group,
data were obtained from the INTERMACS registry. Base-
line demographics included age (in ranges as used by
INTERMACS), sex, heart failure etiology, New York Heart
Association class, history of stroke, body surface area, and
weight. Other baseline data included left ventricular ejection
fraction, hemodynamics (cardiac index), central venous
pressure, pulmonary capillary wedge pressure, pulmonary
vascular resistance, pulmonary arterial pressures, systemic
blood pressure, laboratory values (creatinine, blood urea ni-
trogen, alanine aminotransferase, aspartate aminotransferase,
total bilirubin, serum sodium), and baseline device or medical
therapy (cardiac resynchronization therapy, implantable
cardioverter-deﬁbrillator, ventilator support, intra-aortic balloon
pump, angiotensin-converting enzyme inhibitors, beta blockers,
and inotropes). INTERMACSproﬁleswere only determined for
patients in the PA group, because the clinical trial preceded
the introduction of INTERMACS proﬁles.
Follow-up after device implantation. Post-operative me-
dical care (including inotropic, antiarrhythmic, anticoagu-
lant, and heart failure therapy) was managed according to
each investigator’s and/or clinician’s preference and usual
practice.
Outcomes. The primary endpoint was survival at 2 years
without re-operation to repair or replace the device and/or
disabling stroke (Rankin scale >3). Secondary endpoints
included frequency of adverse events, functional status, and
quality-of-life assessments. Adverse events were deter-
mined for events that had equivalent deﬁnitions in both
studies. Functional assessments and quality-of-life ques-
tionnaires were obtained at baseline when possible before
LVAD implantation and at 3, 6, 12, 18, and 24 months.
Functional status measurements included 6-min walk dis-
tances. Heart failure–related quality of life was assessed
for the PA group using the European Quality of live
5-dimensional utility score, and for the TR group using
the Minnesota Living with Heart Failure (MLWHF) and
the Kansas City Cardiomyopathy questionnaires (KCCQ).
Adverse events were recorded throughout the study until
the analysis cutoff.
Statistical analysis. Data for the PA group were collected
through the INTERMACS registry. Statistical analysis was
performed by the sponsor, Thoratec Corporation. Differ-
ences between groups for independent, normally distributed,
and continuous variables were evaluated using the t test.
Variables that were not normally distributed were evaluated
using the nonparametric Mann-Whitney U test. Differences
in categorical variables were evaluated using Fisher exact test
or the Pearson chi-square test for more than 2 groups.
Survival analysis was performed using the Kaplan-Meier
method, with patients censored for transplantation, recov-
ery of native heart function with device removal, or with-
drawal from the study. Comparison of survival between the
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events were presented as both percentages of patients and
event rates (events per patient-year). Comparison of adverse
event rates between the two groups were performed using
Cochran-Mantel-Haenszel statistics. Adverse events in the
PA group were compared with those for the TR group for
events in which the deﬁnitions were equivalent. Changes for
statistical signiﬁcance over time for EQ-5D and 6-min walkTable 1 Baseline Characteristics
Post-Approval Trial p Value
Age (yrs)
<40 6 (2) 7 (5)
40–59 69 (28) 43 (32) 0.186
60 172 (70) 83 (62)
Male (%) 204 (83) 107 (80) 0.676
Race
White 185 (75) 98 (74)
Black 45 (18) 26 (20) 0.963
Other 17 (7%) 9 (7)
Ischemic etiology (%) 140 (57) 88 (66) 0.080
NYHA class IV (%) 196 (79) 95 (71) 0.099
Body surface area (m2) 2.01  0.29 2.03  0.26 0.505
Weight (kg) 85  22 86  20 0.633
History 87 (35) 52 (39) 0.503
Valve surgery 26 (11) 14 (11) 1.000
Cancer 37 (16) 24 (18) 0.561
Diabetic 105 (43) 63 (47) 0.387
Previous stroke 26 (11) 22 (17) 0.106
Hemodynamics/laboratory
values
Cardiac index, l/min/m2 2.11  0.87 2.06  0.57 0.584
CVP, mm Hg 12.1  6.7 12.9  6.7 0.340
PCWP, mm Hg 24.3  7.5 24.1  8.4 0.767
Systolic BP, mm Hg 105  17 103  15 0.279
Diastolic BP, mm Hg 62  12 60  13 0.162
Creatinine, mg/dl 1.6  0.6 1.6  0.6 1.000
BUN, mg/dl 34  20 38  25 0.165
ALT, U/l 47  74 39  37 0.231
AST, U/l 47  62 36  47 0.088
Total bilirubin, mg/dl 1.3  0.9 1.2  0.8 0.292
Serum sodium, mmol/l 134.9  4.7 134.8  4.3 0.839
Concomitant medications
or interventions
ICD (%) 212 (85) 109 (82) 0.373
Ventilator support (%) 10 (4) 9 (7) 0.323
IABP (%) 61 (25) 30 (23) 0.706
Inotropes (%) 197 (80) 102 (77) 0.513
INTERMACS proﬁle
1 12 (5) NA
2 104 (42)
3 71 (29)
4–7 60 (24)
Values are n (%).
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BP ¼ blood pressure;
BUN ¼ blood urea nitrogen; CVP ¼ central venous pressure; IABP ¼ intra-aortic balloon pump;
ICD ¼ implantable cardioverter-deﬁbrillator; INTERMACS ¼ Interagency Registry for Mechanically
Assisted Circulatory Support; NYHA ¼ New York Heart Association; PCWP ¼ pulmonary capillary
wedge pressure.tests were evaluated using linear mixed-effect modeling. All
comparisons were 2-sided with the level of signiﬁcance set at
p < 0.05. Statistical analyses were performed using SAS
version 9.3 (SAS Institute Inc., Cary, North Carolina).
Results
Baseline characteristics. Baseline parameters were charac-
teristic of extremely ill patients with advanced heart failure
and were similar between groups (Table 1). The percent of
patients older than age 60 years was 70% and 62% for the
PA and TR groups, respectively. INTERMACS proﬁles
were only determined for patients in the PA group, of whom
47% were the most severely ill (proﬁles 1 and 2).
Outcomes. Median duration of support was 2.0 years
(range 0 to 2.6) for the PA group and 1.7 years (longest 6.0)
for the TR group, with a cumulative follow-up duration of
386 and 280 patient-years, respectively. Kaplan-Meier sur-
vival (Fig. 1) at 12 and 24 months for the PA group was
74  3% and 61  3% compared with the TR group of 68 
4% and 58  4% (p ¼ 0.2081; log-rank test). Survival for
the PA group at 12 and 24 months for INTERMACS
proﬁles 4 to 7 was 82  5% and 67  6% compared
with INTERMACS proﬁles 1 to 3 of 71  3% and 59 
4% (p ¼ 0.179 log-rank test) (Fig. 2). The percent of
patients who reached the endpoint of survival free from any
stroke and re-operation to replace the device at 2 years in the
PA group was 54% (135 of 247 patients) compared with
44% (58 of 133 patients) for the TR group (p ¼ 0.042).
Additional subgroup survival analysis showed no difference
in patients younger than and older than age 60 years (Fig. 3),
by sex (Fig. 4), or by race. The median length of initialFigure 1
Survival for Post-Approval Study Versus the
Clinical Trial
Survival in the post-approval group trended to be better than that in the initial
clinical trial, with an absolute difference of 74% versus 68% at 1 year and 61%
versus 58% at 2 years. DT ¼ destination therapy.
Figure 2
Survival for the Post-Approval Study Group by
INTERMACS Proﬁle
Survival trended to be better in patients with INTERMACS proﬁles 4 to 7.
INTERMACS ¼ Interagency Registry for Mechanically Assisted Circulatory Support.
Figure 4 Survival for the Post-Approval Study Stratiﬁed by Sex
There was no difference in survival between men and women.
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PA group versus 27 days in the TR group.
Functional assessment and quality of life. Early and
sustained improvements in quality of life were seen in the PA
group using the EQ-5D visual analog scale and the EQ-5D
total score (Fig. 5). By 3 months, the visual analog scale had
increased approximately 30 points, from 40 to approximately
70, and remained stable through 24 months. Improvements
were noticeable in all 5 components of the EQ-5D: activ-
ities, anxiety, mobility, pain, and self care (Fig. 6). Results for
the trial group have been previously published using theFigure 3 Survival for the Post-Approval Study Group by Age
There was no difference in survival between younger (<60 years) and
older patients.KCCQ and MLWHF questionnaires, which demonstrated
a similar degree of improvement over time (3,4).
Signiﬁcant improvements in functional status over time
as determined by the 6-min walk test were observed in both
the PA and TR groups. Many patients were not able to walk
before LVAD implantation. The 6-min walk distances forFigure 5
Changes Over Time After Left Ventricular Assist
Device Implantation for the Post-Approval Group for
EQ-5D Visual Analog Scale and EuroQoL Total Score
EuroQol scores (lower score¼ improved quality of life) were signiﬁcantly (p> 0.001)
improved after left ventricular assist device implantation, and this improvement
was sustained over the study period.
Figure 6 Changes Over Time of Individual EQ-5D Components
Improvements were noticeable in all ﬁve components of the EQ-5D:
activities, anxiety, mobility, pain, and self-care. QoL ¼ quality of life.
Figure 7
Survival Free of Stroke (Hemorrhagic or Ischemic),
Device-Related Infection, or Pump Replacement
Abbreviation as in Figure 1.
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walked at baseline were 183  97 m and 182  140 m for
the PA and TR groups, respectively, and increased to 297 
118 m and 372  191 m by 24 months.
Adverse events. A comparison of adverse events between
the 2 groups is shown in Table 2. There were reductions or
favorable trends in adverse events between the TR and the
PA patients in most major categories, including bleeding,
device-related infections, ischemic stroke, and overall pump
replacement for all causes, whereas hemolysis was the only
event that trended toward an increase. Figure 7 shows a
signiﬁcant improvement in the Kaplan-Meier estimate of
survival free of stroke, device-related infections, or pump
replacement.Table 2 Adverse Events
Adverse Events
Post-Approv
Patients
Bleeding requiring PRBC 54%
Bleeding: requiring re-exploration 13%
Infection: local nondevice related 39%
Sepsis 19%
Device-related: 19%
Cardiac arrhythmias: cardioverted deﬁbrillation 37%
Renal failure 18%
Right heart failure 18%
RVAD 2.4%
Stroke 11.7%
Ischemic stroke 4.0%
Hemorrhagic stroke 7.7%
Hemolysis 6.5%
Pump thrombosis 3.6%
Pump replacement 4.0%
PRBC ¼ packed red blood cells; RVAD ¼ right ventricular assist device.Discussion
We examined outcomes of the ﬁrst 247 US patients who
received the HM II LVAD as DT in commercial practice
following FDA approval. We then compared these outcomes
with those achieved in the initial clinical trial cohort to see
whether clinical trial outcomes were successfully translated
into commercial practice. Our principal ﬁndings were as
follows:
First, dissemination of the HM II technology PA was
associated with continued excellent results with 1- and
2-year survival of 74% and 61%, respectively. This survival
outcome was independent of age, sex, or race, and not onlyal (N ¼ 247) Trial (N ¼ 133)
Event Rate Patients Event Rate p Value
0.84 81% 1.66 <0.001
0.09 30% 0.23 <0.001
0.59 49% 0.76 0.062
0.18 41% 0.38 <0.001
0.22 35% 0.47 <0.001
0.40 56% 0.69 <0.001
0.15 16% 0.10 0.124
0.16 23% 0.16 0.989
0.02 3.8% 0.024 0.816
0.083 19% 0.13 0.113
0.031 8% 0.06 0.089
0.052 11% 0.07 0.368
0.06 3.8% 0.024 0.057
0.027 3.8% 0.024 0.872
0.026 9.0% 0.057 0.066
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observed in the initial trial (1 year 68%; 2 year 58%).
Second, we observed a lower prevalence of serious adverse
events, namely, bleeding, device-related infection, and stroke
in the PA cohort.
Lastly, and because DT is currently being tested in less
sick patients (INTERMACS proﬁles 4 to 7), it is of
particular note that our survival results in this subgroup
(1 year 82%; 2 year 67%) were the best in any multicenter
cohort described to date.
Our results serve as a reminder that overall improvement
in outcomes of advanced heart failure patients over the past
decade has been nothing less than dramatic (Fig. 8): In
REMATCH (Randomized Evaluation of Mechanical
Assistance for the Treatment of Congestive Heart Failure),
2-year survival of advanced heart failure patients random-
ized to medical therapy (mainly continuation of inotropic
support) was 8% (5–7). Although the HM 1 outperformed
medical therapy at that time, 2-year survival with this pul-
satile device was only 23%. Our results, which showed
2-year survival of 61% in the overall cohort and 67% in less
sick patients, clearly indicate that the hurdle of providing
survival beneﬁt has been more than cleared by currently
available technology. Simultaneously, the bar for future
destination therapy devices has risen from providing mainly
a survival beneﬁt to also improving quality of life with
minimal adverse events. As such, careful patient selection is
paramount and can be guided by risk scores speciﬁcally
developed for patients receiving long-term mechanical cir-
culatory support (8).
The reduction in stroke from 19% to 11.7 % (0.13 to 0.08
events per patient-year) we observed is particularly encour-
aging, because disabling stroke is arguably the adverse event
with the highest negative impact on quality of life. Although
it is unlikely that this complication can be entirelyFigure 8
Current Status Destination Therapy for
Advanced Heart Failure
Current status of left ventricular assist device (LVAD) destination therapy trials
show dramatic improvement with the HeartMate (HM) II continuous-ﬂow LVAD
(current study, plus references [2,3,5]) in comparison with pulsatile ﬂow LVADs
and compared with optimal medical therapy (OMM) over the last decade (6,7).
DT ¼ destination therapy.eliminated, we are hopeful that attention to anticoagulation
therapy and other management practices may lead to a
further reduction in the stroke rate. With regard to infec-
tious complications, there are also encouraging trends, but
transcutaneous energy transfer and the elimination of
drivelines will likely provide the greatest reduction in rate of
infection with future devices.
The observed reduction in the device replacement rate is
likely a function of improved surgical technique and lower
frequency of driveline infections because the reported rate of
device thrombosis was unchanged. Although it is somewhat
difﬁcult to consolidate the increased rate of hemolysis with
a steady rate of device thrombosis because these should go
hand in hand (9), this discrepancy may simply underscore
the wide variety in the clinical management of hemolysis
and diagnosis of device thrombosis between centers (10).
In this context, it is of particular note that the present
datadincluding the hemolysis rate of 6.5% in the PA
cohort on the basis of the previous INTERMACS deﬁni-
tion (plasma free hemoglobin > 40 mg/dl)dwas collected
on device implantations performed before a reported in-
crease in the prevalence of device thrombosis began in 2010
(11) or 2011 (12). Clearly, a prospective study of hemolysis
and device thrombosis using strict deﬁnitions is needed,
and newer generation devices and improved management
practices should aim to eliminate both.
Our results in the real world should further encourage
cardiologists who are familiar with the clinical trial results to
discuss DT with their patients. Such discussions should
entail the distinct survival beneﬁt of CF mechanical circu-
latory support in advanced heart failure, without omitting the
still highly signiﬁcant adverse event burden, including the
need for readmission for device-related complications (13).
Study limitations. The principal limitation of this pro-
spective study is that data for the PA cohort were collected
through INTERMACS. Adverse events were reported by
treating physicians and not adjudicated by a clinical events
committee. We do not believe that this form of data collec-
tion had any effect on our major endpoint (survival), but we
cannot exclude underreporting of minor adverse events.
Conclusions
In summary, we report excellent survival in the ﬁrst 247
patients treated in a commercial setting with the HM II
LVAD as DT. Although randomization to medical therapy
for ethical reasons is no longer possible in this setting, we
believe that the results seen here likely exceed those that
would have been seen with medical therapy by a survival
difference of approximately 50% (absolute). Although it is
clear that further improvement in survival should occur, and
further reduction in serious adverse events must occur to
make LVAD therapy the right choice for heart failure pa-
tients who are less sick, we believe that our data reﬂect the
state of the art, and as such, set the bar for all future en-
deavors in circulatory support as DT.
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